477889-91-1

Usage

Uses

Used in Organic Synthesis:
2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-5-IODOPYRIDINE is used as a building block in organic synthesis for creating various molecular structures with specific biological and pharmacological properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-5-IODOPYRIDINE is utilized as a building block to develop new drugs with targeted therapeutic effects. Its unique structure allows for the creation of molecules that can interact with specific biological targets, potentially leading to the discovery of novel treatments for various diseases and conditions.

Upstream product

• 20511-12-0 2-amino-5-iodopyridine 
• 110-13-4 2,5-hexanedione 

Downstream Products

• 638352-78-0 1-(5-methoxypyridin-2-yl)-2,5-dimethyl-1H-pyrrole 
• 1936529-65-5 3-(2-chloro-6-methylphenyl)-7-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one 
• 1083329-33-2 2-N-(2,5-dimethylpyrrolo)-5-benzyloxypyridine 
• 139585-48-1 2-chloro-5-methoxypyridine 
• 10167-97-2 2-amino-5-methoxypyridine 

Relevant academic research and scientific papers

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

Rapid and efficient trifluoromethylation of aromatic and heteroaromatic compounds using potassium trifluoroacetate enabled by a flow system

Going to the source: The trifluoromethylation of aryl/heteroaryl iodides has been demonstrated using a flow system, thus enabling a rapid rate of reaction. A broad spectrum of trifluoromethylated compounds was prepared in good to excellent yields using CF3CO2K as the trifluoromethyl source. The process has the advantage of short reaction times and uses convenient [CF3] sources. Copyright

Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis

Herein we report an investigation of the efficacy of pyridine and pyrimidine analogs of acetaminophen (ApAP) as peroxyl radical-trapping antioxidants and inhibitors of enzyme-catalyzed lipid peroxidation by cyclooxygenases (COX) and lipoxygenases (LOX). I

A simple Cu-catalyzed coupling approach to substituted 3-pyridinol and 5-pyrimidinol antioxidants

(Chemical Equation Presented) A convenient approach to 3-pyridinols and 5-pyrimidinols via a two-step Cu-catalyzed benzyloxylation/catalytic hydrogenation sequence is presented. The corresponding 3-pyridinamines and 5-pyrimidinamines can be prepared in an analogous sequence utilizing benzylamine in lieu of benzyl alcohol. The radical-scavenging ability of these derivatives are preliminarily explored and reveal that the increased acidities of the pyridinols and pyrimidinols render them susceptible to more significant kinetic solvent effects when compared to phenols.

HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES

HIV inhibitory compounds of formula (I) salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R1 is halo, cyano, nitro, C1-6alkyl, polyhaloC1-6alkyl, -C1-6alkyl-OR4, -C(=O)-R5, -C(=O)-OR4, -C(=O)-NR6R7, -OR4, -O-C(=O)-C1-6alkyl, -O-C1-6alkyl-OR4, -O-C1-6alkyl-NR6R7, -O-C1-6alkyl-O-C(=O)-C1-6Alkyl, -O-C1-6alkyl-C(=O)-OR4, -O-C1-6alkyl-C(=O)-NR6R7, -NR6R7, -NR8-C(=O)-R5, -NR8-C(=O)-OR4, -NR8-C(=O)-NR6R7, -NR8-C(=O)-C1-6lkyl-C(=O)-OR4, -NR8-C1-6alkyl-OR4, -NR8-C1-6alkyl-NR6R7, -NR8-C1-6alkyl-imidazo lyl, -NR8-SO2R9, -N=CH-NR6R7, -NH-C(=NH)-NH2, -SO2NR6R7, and -O-PO(OR8)2; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R2 is C1-6alkyl, polyhaloC1-6alkyl, halo, cyano, -COOR4, -OR4, and -NR6R7; R3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.

Synthesis of Differently Disubstituted 2,2′-Bipyridines by a Modified Negishi Cross-Coupling Reaction

A general practical approach to a number of differently disubstituted 2,2′-bipyridines from substituted 2-bromo- and 2-chloropyridines by application of modified Negishi cross-coupling conditions has been developed. These 2,2′-bipyridines carry versatile functional groups that can be elaborated further, as demonstrated for some examples. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.